Emdrix Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 1.09 M
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 2.00 Cr
- Revenue Growth 72.67%
- Profit Growth -3430.09%
- Ebitda -628.13%
- Net Worth -345.77%
- Total Assets 56.89%
About Emdrix Pharmaceuticals
Emdrix Pharmaceuticals Private Limited (EPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 03 September 2012 and has a history of 12 years and five months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.09 M.
The company currently has active open charges totaling ₹2.00 Cr.
Hindupur Udayasimha, Subbaraju Narasimha, Namitha Ananth, and Two other members serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85191KA2012PTC065703
- Company No.
065703
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2012
- Date of AGM
30 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Emdrix Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hindupur Udayasimha  | Whole-Time Director | 03-Sep-2012 | Current |
| Subbaraju Narasimha | Whole-Time Director | 03-Sep-2012 | Current |
| Namitha Ananth | Whole-Time Director | 03-Sep-2012 | Current |
| Sharmarashmi | Whole-Time Director | 03-Sep-2012 | Current |
| Niranjan Shetty | Director | 16-Jul-2016 | Current |
Financial Performance of Emdrix Pharmaceuticals.
Emdrix Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 72.67% increase. The company also saw a substantial fall in profitability, with a 3430.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 345.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emdrix Pharmaceuticals?
In 2017, Emdrix Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ensur Tekserv Unified Private LimitedNiranjan Shetty is a mutual person
Charges (Loans)
₹20.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Mysore : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 May 2015 | State Bank Of Mysore | ₹2.00 Cr | Open |
How Many Employees Work at Emdrix Pharmaceuticals?
Emdrix Pharmaceuticals has a workforce of 1 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emdrix Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emdrix Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
